GNT Pharma’s Crisdesalazine Undergoing Phase 1b Clinical Trial for Alzheimer’s
GNT Pharma’s Crisdesalazine Undergoing Phase 1b Clinical Trial for Alzheimer’s
  • Hyun Duk Yang
  • 승인 2021.11.26 14:28
  • 댓글 0
이 기사를 공유합니다

Inhibits mPGES-1
Scavenges ROS species

GNT Pharma, headquartered in Yongin, South Korea, is a biotechnology company developing innovative drugs for the treatment of neurological diseases including Alzheimer’s disease (AD).

GNT Pharma developed its novel drug ‘Crisdesalazine (also known as AAD-2004)’ for the treatment of canine cognitive dysfunction syndrome (or dementia in dogs) and commercialized it successfully under the product name of ‘ZedaCure’ in February this year.

Crisdesalazine has anti-inflammatory effects by inhibiting the action of microsomal prostaglandin E synthase-1 (mPGES-1), an inducible enzyme that synthesizes proinflammatory PGE2 and is over-expressed in the AD brains. Crisdesalazine also has anti-oxidant effects. In the AD animal models, crisdesalazine showed anti-amyloid and anti-tau effects.

Based on that canine dementia is an age-related neurodegenerative disease with the brain pathologies similar to those in human AD and that crisdesalazine showed the therapeutic efficacy in canine dementia, the company expects that crisdesalazine may give hope for the treatment of AD in humans.

After completing its phase 1a clinical trial (single ascending dose trial) of crisdesalazine for the AD patients in 2017, the company has currently been undergoing its phase 1b study that is expected to be completed by the first quarter of next year. The company will apply for its phase 2 studies as soon as it completes the phase 1b study.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.